• Click here for the Objective & Executive Summary
  • A must-attend, 2-day "immersion" training program specifically designed for pharmaceutical industry executives who are new or relatively new to lung cancer therapeutics, supportive care products and diagnostics.
  • Highly interactive format used at the very successful previous Master Class so you can establish your personal relationships with lung cancer KOLs.
  • The focus is proportionately on the most common and most practical topics involving lung cancer. For example, a limited amount of time will be devoted to early-stage NSCLC and a larger amount of time on the agenda will address advanced or metastatic NSCLC.
  • This lung cancer Master Class is also an excellent 2-day review for experienced pharmaceutical industry executives who wish to be completely up-to-date on lung cancer.
  • A highly interactive learning format which allows the participants to be closely engaged with the faculty throughout the entire 2-day program.

Dara Aisner, MD, PhD
Assistant Professor
Department of Pathology
Co-Director of the Colorado Molecular Correlates Laboratory
University of Colorado School of Medicine
University of Colorado Cancer Center
Denver, CO

Hossein Borghaei, DO
Chief, Division of Thoracic Medical Oncology
Director, Lung Cancer Risk Assessment
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Paul Bunn, Jr., MD
Distinguished Professor
Division of Medical Oncology
University of Colorado Denver
James Dudley Chair in Lung Cancer Research, Denver, CO
Past President of the American Society of Clinical Oncology,
Past Executive Director of the International Association for the Study of Lung Cancer

Walter J. Curran, Jr.,MD
Walter J. Curran, Jr.,MD
Executive Director, Winship Cancer Institute
Associate Vice President, Cancer,
Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG
Atlanta, GA

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Assistant Professor of Nursing
Division of Acute Care/Health Systems
Thoracic Oncology Program
Yale School of Nursing
Yale Cancer Center
New Haven, CT

Shirish M. Gadgeel, MD
Director of the Thoracic Oncology program
Karmanos Cancer Center
Wayne State University
Detroit, MI

Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Richard Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, NY

Fred Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO

Jim Koeller, MS
Professor
University of Texas at Austin
College of Pharmacy
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine
Pharmacotherapy Education & Research Center
San Antonio, TX

Steve Madison
President and CEO
Oncology Learning Center, Inc., and the
BioMedical Learning Institute
Plano, TX

Ronald B. Natale, MD
Director
Lung Cancer Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Suresh Ramalingam, MD
Professor of Hematology/Oncology
Deputy Director
Winship Cancer Institute
Director, Lung Cancer Program
Winship Cancer Institute
Assistant Dean for Cancer Research
Co-Leader, Discovery & Developmental Therapeutics Program
Emory University
Atlanta, GA

Gregory J. Riely, MD, PhD
Medical Oncologist
Thoracic Oncology Service
Vice Chair,
Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Joan H. Schiller, MD
Member, Inova Medical Group
Lung Cancer Group
Hematology/Oncology
Inova Schar Cancer Institute
Falls Church, VA

Mark Socinski, MD
Executive Medical Director,
Florida Hospital Cancer Institute
Orlando, FL

Anne S. Tsao, MD
Associate Professor
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas MD Anderson Cancer Center
Houston, TX

Jared Weiss, MD
Assistant Professor
Division of Hematology and Oncology
School of Medicine
Clinical Research
Thoracic Oncology Program
University of North Carolina
Chapel Hill, NC

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

GROUP DISCOUNTS WHILE AVAILABLE · Register Now
120
120
The Lung Cancer Master Class is full. You may send an email to registration@oncologylearningcenter.com if you would like to be placed on a waiting list.
Day 1 - February 2, 2017 Dr. H. Jack West is Co-Chair for Day 1.
7:00AM
CHECK-IN
7:00AM
BUFFET BREAKFAST
8:00AM
WELCOME, INTRODUCTIONS, OBJECTIVES & CME/CE PRE-TEST
Steve Madison
RAPID-FIRE Questions
  1. I am new to lung cancer but I have worked on another malignancy in my previous job. Yes? No?
  2. I am new to lung cancer but I have worked completely outside of cancer in my previous job. Yes? No?
  3. I have been working in the field of lung cancer for approximately one year and I still believe that I have much more to learn. Yes? No?
Content Highlights
  • This 2-day "immersion" training program has been specifically designed for pharmaceutical industry executives who are new or relatively new to lung cancer therapeutics, supportive care products and diagnostics.
  • The highly-interactive learning format and the ratio of participants to faculty (approximately 120 participants to 20 faculty) will help participants establish personal relationships with the KOL lung cancer experts. There’s a private reception, a private dinner with one KOL at each table with 7 participants; two full breakfasts and lunches, plus numerous breaks throughout the meeting and Q&A sessions will provide ample time to meet the KOLs.
  • The focus is on the most important information for Pharmaceutical Executives & Health Care Professionals (HCPs) who are new or relatively new to lung cancer. The content is proportionately on the most common and most practical topics involving lung cancer. For example, a limited amount of time will be devoted to early-stage NSCLC and a larger amount of time on the agenda will address advanced or metastatic NSCLC. This will be addressed in this intensive, CME/CE, advanced-level, 2-day immersion training program. It has been carefully planned with input from numerous potential participants. This Lung Cancer Master Class is devoted to the clinical and commercial aspects of lung cancer which are essential to pharmaceutical executives in R&D, Clinical Development, Medical Affairs, Strategic & New Product Planning, Marketing, and related functions.
8:30AM
EPIDEMIOLOGY, ETIOLOGY OF LUNG CANCER & THE INCREASING IMPORTANCE OF LUNG CANCER DIAGNOSTICS
Jared Weiss
RAPID-FIRE Questions
  1. Lung cancer is the #1 cause of cancer deaths in the world. True? False?
  2. Small Cell Lung Cancer (SCLC) represents approximately 50% of all lung cancers? True? False?
  3. Approximately 10% of lung cancers occur in never smokers. True? False?
Content Highlights
  • New cases versus death are a true unmet need (magnitude) show chart from Facts & Figures
  • Brief pathology review (100% needed to make a cancer DX); Staging before testing and diagnostics
  • Causes & Risk factors: Hereditary, Genetics, Mutations
  • CT Chest Scans and other imaging scans
  • Non-Small Cell Lung Cancer (NSCLC) versus Small Cell Lung Cancer (SCLC)
8:50AM
Q & A
9:00AM
THE “DRIVERS” OF LUNG CANCER: KEY MUTATIONS - EGF, ALK, ROS1,VEGF & more…
Suresh Ramalingam
RAPID-FIRE Questions
  1. I understand what is meant by a “driver mutation” in lung cancer. Yes? No?
  2. The primary “drivers” (actionable mutations) of lung cancer are EGF, ALK and PD-L1. True False?
  3. For treatment-naïve lung cancer patients, oncologists should initiate anti-cancer treatment with chemotherapy while they wait for actionable mutation test results. True? False?
Content Highlights
  • Traditional NSCLC Subtypes: squamous, adenocarcinoma, large cell (nonsquamous)
  • What are the required, essential, traditional molecular tests and why are they used initially: IHC, FISH, and other molecular tests?
  • Why are all ICH and FISH tests not the same? Who does them? Standardization.
  • The clinical significance & implications of identification mutations on prognosis and therapy selection
  • Beyond EGF, ALK ROS1 and VEGF and their clinical significance and implications: MET1, V20, KRAS, CDK4, CDK6, BRAF, HER2, MEK: Who has these? Bad? Good? Why?
  • Anything else?
9:20AM
Panel Discussion on driver mutations - Moderator: H. Jack West (Master Class Co-Chair)
9:40AM
BREAK
10:00AM
 TESTING FOR LUNG CANCER: TRADITIONAL vs. NEXT-GENERATION SEQUENCING TESTING
Dara Aisner
RAPID-FIRE Questions
  1. I understand the difference between a companion diagnostic and a complementary diagnostic. Yes? No?
  2. I know how Next Gen Sequencing (NGS Testing) differs from Testing for IHC, FISH & PCR in lung cancer: Yes? No?
  3. I understand what is called a liquid biopsy used in the management of NSCLC: Yes? No?
  4. I understand what to do when an NGS panel identifies a genetic mutation that identifies a commercially available drug to treat the patients but it is not yet FDA approved. Yes? No?
Content Highlights
  • What is the value of Next Generation Sequencing versus traditional IHC, FISH or PCR? Why?
  • Gene Signatures: prognostic vs predictive genetic mutations; CTCs & circulating Free DNA
  • Liquid biopsies versus gene signature panels: pros & cons; what is the specific place for liquid biopsies?
  • At disease recurrence, what next? Rebiopsy? If so What method: tissue or liquid and why?
  • Clinical Implications of NGS: Leading to Standards of Care versus investigational use; which patients?
10:20AM
 DEBATE #1: Next Generation Sequencing (NGS) testing is sufficiently reliable to be used as an alternative to identify driver mutations as a substitute for needle biopsies of lung cancer tissue. Debate Moderator: H. Jack West
YES: Suresh Ramalingam
NO: Dara Aisner
10:40AM
Expert Panel Discussion and Q & A
10:55AM
 SMALL CELL LUNG CANCER THERAPEUTIC OPTIONS
Joan Schiller
RAPID-FIRE Questions
  1. SCLC represent about 50% of all lung cancers. True? False?
  2. The standard of care using a chemotherapy doublet has changed approximately how many times in the past 25 years. A) 1 B) 2 C) 3 4) Never
  3. The only FDA approved drugs for SCLC are chemotherapeutics. No immune therapy nor targeted therapy are FDA approved today. True? False?
Content Highlights
  • Single-agent therapy vs. double therapy, versus triple-drug therapy vs. radiation
  • Limited Disease, patient prognoses and overall patient management
  • Extensive Disease, patient prognoses and overall patient management
  • Role of Radiation with chemotherapy: Prophylactic cranial Irradiation & chest radiation
  • Standards of Care vs. Investigational therapies in clinical trials; Initial & salvage
11:15AM
Q & A
11:25AM
EARLY-STAGE NON-SMALL CELL LUNG CANCER
Hossein Borghaei
RAPID-FIRE Questions
  1. The majority of early-stage lung cancers (Stages I-III) are cured by surgery & radiation. True? False?
  2. Treatment-naïve early-stage disease NSCLC patients should be tested for actionable, druggable mutations prior to initiation of their systemic anti-lung cancer therapy. True? False? Uncertain?
  3. With NGS testing, “driver mutations” have been identified in NSCLC patients with early-stage disease enabling the use of targeted therapies for these patients. This is an example of evidenced based medicine. True? False?
Content Highlights
  • Defining early-stage NSCLC patients: Staging, Prevalence, Incidence; Goals of Therapy: Why different?
  • Clinical Implications on prognosis and therapy decisions of detecting lung cancer early
  • Multidisciplinary (pathology, surgery, radiation (DX+TX), medical oncology, other HCPs)
  • Adjuvant versus Neo-adjuvant
  • Locally-Advanced Disease
  • Why is Stage IIIA vs. IIIB so important? (e.g., Cisplatin vs Carboplatin-based regimens)
  • Systemic options: chemotherapy, targeted therapy, immune therapy
  • Other Key Concepts: Pancoast Tumors? Chemoradiation? SBRT?
  • Standards of Care vs. Investigational use in clinical trials (including targeted therapies & immune therapies)
11:45AM
Expert Panel Discussion and Q & A - Moderator: H. Jack West
12:00PM
 "LUNCH WITH THE PROFESSORS" - Participants have lunch with the KOL lung cancer expert of their choice.
1:00PM
THE INCREASINGLY VITAL ROLE OF SUPPORTIVE AND PALLIATIVE CARE IN LUNG CANCER
Richard Gralla
RAPID-FIRE Questions
  1. I understand the roles of “palliative” & “supportive” care for lung cancer. Yes? No? Maybe?
  2. Supportive care includes hospice Yes? No? Maybe?
  3. Supportive care should be initiated at the start of systemic anti-cancer therapy. Yes? No? Maybe?
Content Highlights
  • Why is it so important to initiate supportive/palliative care at the same time as starting anticancer drug therapy?
  • Review of the common supportive care interventions for lung cancer: Control of nausea and vomiting, loss of appetite, fatigue, depression, anxiety, pain, etc., and the role of growth factors
  • What is the importance of quality of life as it relates to palliative and supportive care?
  • Standards of care vs. Investigational use in clinical trials
1:20PM
Q & A
1:30PM
DEBATE #2: Most community oncologists understand the clinical applications of Radiation Therapy for lung cancer and therefore, utilize Radiation Therapy appropriately. Debate Moderator: H. Jack West
YES: Hossein Borghaei
NO: Wally Curran
1:50PM
Expert Panel Discussion and Q & A - Moderator: H. Jack West
2:10PM
BONE METASTASES IN LUNG CANCER
Wally Curran
RAPID-FIRE Questions
  1. The prevalence of bone metastases is approximately 5 to 10% in lung cancer patients. True? False? Uncertain?
  2. Choices to treat bone metastases include direct radiation and drug therapy. True? False?
Content Highlights
  • Prevalence of bone metastases in lung cancer patients
  • Implications of not managing bone metastases in lung cancer patients
  • Standards of care versus Investigational use of treatments in clinical trials
  • Pros and cons of bisphosphonates and the monoclonal Antibody against Rank Ligand
  • Pros and cons of Radium Ra 223 dichloride
2:30PM
Q & A
2:50PM
BREAK
3:20PM
PLEURAL EFFUSIONS IN LUNG CANCER
Anne Tsao
RAPID-FIRE Questions
  1. A lung cancer patient with a fluid collection in the pleural space surrounding the lung (which is normally empty) is considered to have a pleural effusion. Yes? No? Maybe?
  2. What stage is a lung cancer patient with a pleural effusion? Stage III? Stage IV?
  3. In most patients with advance lung cancer the pleural effusion is caused by the cancer. Yes? No?
Content Highlights
  • Why is this such an important topic?
  • The prevalence, clinical significance, and impact and therapy of pleural effusions on NSCLC therapy
  • Pleural effusions in NSCLC and Mesothelioma
  • Standards of care versus Investigational use of treatments in clinical trials
3:40PM
Q & A
3:50PM
STAGE IV NSCLC: OVERVIEW OF THERAPEUTIC OPTIONS & DECISION MAKING, NOW, AND IN THE VERY NEAR FUTURE
H. Jack West
RAPID-FIRE Questions
  1. I understand the difference between “advanced lung cancer and “stage IV lung cancer.” Yes? No?
  2. The majority of NSCLC patients will eventually reach Stage IV. True? False?
  3. Next Generation (NGS) testing should be done on all treatment-naïve advanced or stage IV NSCLC patients. True? False?
  4. Now that each of the 3 different classes of systemic therapy (chemo, targeted, Immune) has at least one or more FDA-approved drugs in all lines of therapy, the overall treatment of lung cancer therapy (algorithm) is now generally well established. True? False?
  5. Approximately 25% of all cancer patients enroll in a clinical trial. True? False?
Content Highlights
  • Chemotherapy vs Targeted Therapy vs. Immune Therapy & vs. Combined Modality Therapy vs. Sequential Therapy
  • The importance of chemotherapy as a therapy backbone: Increasing? Diminishing? Unchanged?
  • The critical role of investigational therapy in clinical trials: How to find trials and enroll?
  • Off-Label Therapy: For which patients might this strategy be appropriate and in which settings?
  • The “value proposition.” Why is value so important versus fee for service?
  • Review the new term: “financial toxicity.” A brief review of value guidelines and 2018.
  • Palliative Care and Hospice: When to stop therapy? A decision involving the patient/family
4:10PM
Q & A
4:20PM
DEBATE #3: Lung cancer patients should not be considered eligible for full doses of chemotherapy if they are 65 years of age and older. Debate Moderator: H. Jack West
YES, they should be considered to receive full doses: Jared Weiss
NO, they should not be considered to receive full doses: Joan Schiller
4:40PM
Expert Panel Discussion and Q & A - Moderator: H. Jack West
5:00PM
Day ONE Sessions Completed
6:00PM
RECEPTION for MEETING the LUNG CANCER KOL Faculty, and Networking with Industry Colleagues. This is a rare opportunity for pharmaceutical industry participants to meet and establish and/or strengthen relationships with lung cancer KOLs & also an for lung cancer industry colleagues, advertising agencies and consultants to network with their colleagues in therapeutic, diagnostic and supportive care companies.
7:00PM
"DINNER WITH THE PROFESSORS" This is one of the best of opportunities during this Master Class to meet with and initiate relationships with lung cancer KOLs. Participants choose to sit with the KOL lung cancer expert of their choice for in-depth discussions and establishing relationships. One KOL is assigned a table and this is an opportunity for 7 participants on a first-come basis to have dinner with the KOL of their choice.
8:00PM
ADJOURN
To register now click here or call 214-269-2014.
Day 2 - February 3, 2017 Dr. Paul Bunn is Co-Chair for Day 2.
7:00AM
BUFFET BREAKFAST
8:00AM
ADENOCARCINOMA OF THE LUNG: STAGE IV THERAPIES AND DECISION MAKING
Paul Bunn
RAPID-FIRE Questions
  1. A Platinum doublet is still the standard of care for Stage IV NSCLC of adenocarcinoma histology. True? False? Uncertain?
  2. An FDA-approved option for treatment-naïve NSCLC patients of adenocarcinoma histology is immune therapy with a checkpoint inhibitor? True? False? Uncertain?
Content Highlights
  • For which NSCLC patients of adenocarcinoma histology is a platinum-based doublet therapy a standard of care for treatment-naïve stage IV NSCLC? The importance of ECOG 1594.
  • For which NSCLC patients of adenocarcinoma histology is immune therapy an option for treatment-naïve adenocarcinoma of Stage IV NSCLC?
  • Is chemotherapy for adenocarcinoma of the lung slowly being replaced by novel targeted and immune therapies?
  • What are the maintenance or switch therapy options after 1st line therapy for adenocarcinoma of the lung?
  • Second-line therapy for adenocarcinoma of the lung: What is next after progressive disease following initial or maintenance/switch therapy?
  • When is “time to chemotherapy” a valid clinical endpoint?
  • What are the third-line options for NSCLC of adenocarcinoma histology?
  • Standards of care and Investigational clinical trials (including novel chemo, targeted & immune therapies)
  • What is on the near-term horizon for NSCLC of adenocarcinoma histology?
8:20AM
Q&A
8:30AM
SQUAMOUS CELL CARCINOMA OF THE LUNG: STAGE IV THERAPIES AND DECISION MAKING
Mark Socinski
RAPID-FIRE Questions
  1. Is a Platinum doublet still a standard of care for treatment-naïve squamous cell stage IV NSCLC. Yes? No?
  2. For squamous cell NSCLC treatment-naïve NSCLC patients many oncologists initiate therapy with an immune oncology therapy? True False?
  3. The current FDA-approved drugs available as options for treatment-naïve NSCLC patients include: chemotherapy, targeted therapy and immune therapy. Yes? No? Uncertain.
Content Highlights
  • Update on Targeted Therapies
  • Update on Chemotherapy
  • Update on Immune Therapy
  • What is on the near-term horizon for NSCLC of squamous histology?
  • How will value-based care and reimbursement impact the selection and use of various options for squamous cell NSCLC?
8:50AM
Q&A
9:00AM
DEBATE #4: What should be the standard of care with FDA-approved agents for Initial therapy for metastatic “squamous” NSCLC? Debate Moderator: Paul Bunn
Chemotherapy doublet plus EGFR MAb: Mark Socinski
Immune Therapy: Edward Garon
9:20AM
Expert Panel Discussion and Q&A Moderator: Paul Bunn
9:40AM
MAINTENANCE AND SALVAGE THERAPY FOR SQUAMOUS CELL NSCLC IN THE ERA OF NOVEL TARGETED, CHEMOTHERAPY, AND IMMUNO-ONCOLOGY THERAPY
Ron Natale
RAPID-FIRE Questions
  1. I understand the difference between switch and continuation maintenance therapy. Yes No?
  2. The options for initial therapy for second-line NSCLC have changed significantly within the past few months. Yes? No?
  3. Is maintenance therapy with immuno-oncology therapy checkpoint inhibition a viable standard of care option for squamous cell lung carcinoma Yes? No?
  4. Although two relatively new targeted therapies were FDA approved for squamous cell in the second line setting for NSCLC their clinical applications have changed significantly because of FDA approval for immune therapy in the second line setting. Yes? No?
Content Highlights
  • What are the maintenance or switch therapy options after 1st line therapy for squamous cell carcinoma?
  • Second-line therapy: Many new options have emerged during the last year. Targeted therapies, novel uses of chemotherapies, immune therapies. What are their pros and cons.
  • What is next after progressive disease following initial or maintenance/switch therapy?
  • What are the third-line options for squamous cell NSCLC? Systemic therapies or supportive care?
  • Are their open and enrolling Investigational Clinical Trials (including novel chemo, targeted & immune therapies) for refractory squamous NSCLC?
10:00AM
 Q&A
10:10AM
 BREAK
10:25AM
 IMMUNOTHERAPIES: THE NEWEST CLASS OF THERAPEUTIC OPTIONS FOR NSCLC, INCLUDING APPLICATIONS ACROSS ALL LINES OF THERAPY
Edward Garon
RAPID-FIRE Questions
  1. After the ESMO 2016 data is it now clear that all treatment-naïve NSCLC patients should be tested for PD-L1 levels? Yes? No? Uncertain?
  2. All treatment-naïve NSCLC cancer patients should be measured for their PD-L1 levels prior to initiation of Immune therapy? Yes? No? Uncertain?
Content Highlights
  • Have Checkpoint inhibition antibodies defined a new subset of the NSCLC “pie?”
  • Have Checkpoint inhibition antibodies established clinical applications and roles in both initial and salvage settings? For which patients?
  • Is there a subset of patients for which PD-L1 testing should NOT be done in the second-line? Why?
  • How reliable and important is PD-L1 as a biomarker? Is it essential? What are the risk of false test results?
  • How has the October 2016 ESMO data from at least 2 key trials changed the paradigm for using immune therapy in lung cancer?
10:45AM
 Q&A
10:55AM
 DEBATE #5: All treatment-naïve NSCLC patients should be tested for PD-L1 status as part of their complete array of initial diagnostic tests before devising an initial systemic anti-cancer systemic therapy plan? Debate Moderator: Paul Bunn
YES: Paul Bunn
NO: Edward Garon
11:15AM
Expert Panel Discussion and Q&A Moderator: Paul Bunn
11:30AM
CURRENT APPPLICATIONS AND NEAR-TERM ADVANCES WITH IMMUNE THERAPY FOR STAGE IV NSCLC
Paul Bunn
RAPID-FIRE Questions
  1. Now that there is an FDA-approved immune therapy for treatment-naïve NSCLC patients, the optimal duration of Immune therapy for NSCLC has finally been established for patients who are responding with either a CR or stable disease. Yes? No? Uncertain?
  2. Now that the FDA has approved an Immune therapy (checkpoint inhibitor) for treatment-naïve NSCLC patients, and has also approved two checkpoint inhibitors for the second-line setting, there is little room for additional treatment strategies involving checkpoint inhibitor immune therapies. True? False?
  3. Today, there are approximately how many immune therapy checkpoint inhibitors under clinical development? A) 4 or less B) 5 to 10 C) More than 10
  4. The ultimate future of Immune therapy in the first-line treatment-naïve setting is in combination with either another immune therapy, a targeted agent or with chemotherapy. Yes? No? Uncertain?
Content Highlights
  • What is the optimal duration of immune therapy for NSCLC? Should a patient in remission stop therapy?
  • Clinical trials & off-label use of Immune therapy in Stages I-III disease? Justified or not?
  • Clinical endpoints and related issues for Checkpoint Inhibition: Time to Response, Pseudoprogression, what is revealed by the “tail of the curve” with immune therapies versus Response Rates with non-immune therapies?
  • Combinations of checkpoint inhibitors with other checkpoint inhibitors: Current data? Outlook?
  • Combinations of checkpoint inhibitors with targeted therapies and chemotherapy Current data? Outlook?
  • Sequencing both immune and targeted therapies? Outlook?
  • New & emerging checkpoint inhibitors for lung cancer: Which? When? For whom and where to use?
11:45AM
Expert Panel Discussion and Q&A Moderator: Fred Hirsch
NOON
 "LUNCH WITH THE PROFESSORS" - Participants sit with the KOL lung cancer expert of their choice.
1:00PM
MANAGING TOXICITIES WITH IMMUNE THERAPIES? WHAT HAVE WE LEARNED IN 6 YEARS? WHAT CHALLENGES DOES THE FUTURE PRESENT?
Marianne Davies
RAPID-FIRE Questions
  1. After nearly a decade of experience with immune therapy checkpoint inhibitors, primarily in melanoma and lung cancer, most community-based oncologists are comfortable using immune therapies and managing their toxicities. True? False?
  2. In some practices (both private and academia) the patient is sometime “demanding” immune therapy for their lung cancer despite the evidence that a targeted therapy of a chemotherapy is clearly the optimal choice as documented by the published literature and guidelines. True? False?
Content Highlights
  • What are the most common types of toxicities associated with immune therapy for lung cancer?
  • One way to learn about these toxicities is analogous to auto immune disease.
  • The oncology nurse or Nurse Practitioner is critically important for successful use of immune therapy.
  • Shared decision making and patient-centered care are part of the new treatment and patient management paradigm using immune therapy for lung cancer.
  • What will the future bring with combinations of either dual checkpoint inhibition of checkpoint inhibition plus a targeted therapy
  • What are we learning from the treatment of melanoma with combination regimens using immune therapy?
1:20PM
Q&A
1:30PM
EGFR-DIRECTED THERAPY FOR STAGE IV NSCLC: DECISION MAKING IN TODAY'S BROADENING EGFR LANDSCAPE
Gregory Reily
RAPID-FIRE Questions
  1. Now that there are three generations of EGFR-Directed therapies, the standards of care are fairly-well established. True? False? Uncertain?
  2. Testing for the T790M mutation should be done on all treatment-naïve patients with NSCLC. True? False? Uncertain?
  3. When an EGFR-positive lung cancer patient fails after 3 lines of therapy they should be enrolled in a clinical trial. True? False? Uncertain?
Content Highlights
  • EGFR mutation-positive NSCLC versus EGFR-negative NSCLC
  • Differences among the numerous EGFR mutations (exon 19 deletion, exon 21 L858R, T790M Mutation, etc.)
  • Differences (including combinations) among three generations of anti-EGFR therapies
  • Adding anti-VEGF TX to anti-EGFR regimens: Impact, benefit? Which patients? Why?
  • EGFR TKI options with or without docetaxel. Which patients? Why?
  • Defining and explaining acquired resistance to EGFR-directed therapy
  • What is the clinical significance of Oligoprogressive disease?
  • Repeat Biopsies Identifying T790M: When and for which patients? Liquid or Tissue-based?
  • Should EGFR TKIs be continued with chemotherapy after developing acquired resistance?
  • What is the role of EGFR TKIs after acquired resistance? With chemotherapy? Other RX?
  • Third-generation EGFR TKIs and combination strategies: Is their role established?
  • Standards of Care versus Investigational therapies use vs off-label use
1:50PM
Q&A
2:00PM
DEBATE #6: When a NSCLC patient relapses on initial EGFR-directed therapy, and tests negative for T790M Mutation. What should be next? Debate Moderator: Paul Bunn
Immune-Oncology therapy: Fred Hirsch
3rd-Generation EGFR-directed therapy: Gregory Reily
2:20PM
Expert Panel Discussion and Q&A Moderator: Paul Bunn
2:40PM
BREAK
3:00PM
ALK-DIRECTED TARGETED THERAPIES FOR STAGE IV NSCLC: DECISION MAKING IN TODAY'S LANDSCAPE
Shirish Gadgeel
RAPID-FIRE Questions
  1. Second and third-generation anti-ALK drugs are more effective for treating CNS disease in patients with the ALK-rearrangement. True? False?
  2. Does the MET exon 14 mutation impact anti-ALK therapy with the MET exon 14 mutation? Yes? No?
  3. What are the implications of ROS1, BRAF, KRAS, RET, HER2 & other new & emerging molecular targets: 1st & 2nd- line therapies for ALK –positive lung cancer: Established? or Uncertain?
Content Highlights
  • Sequencing lines of FDA-approved anti-ALK therapy & emerging anti-ALK therapies
  • Managing CNS Involvement in ALK –Positive NSCLC
  • What is the impact on anti-ALK therapy with MET exon 14 mutations?
  • Standards of Care vs. Investigational therapies (Clinical Trials)
3:20PM
Q&A
3:40PM
DEBATE #7: A patient has progressed on crizotinib, and then was placed on second-line alectinib, and again subsequently progressed. What next? Debate Moderator: Paul Bunn
Another anti-ALK: Shirish Gadgeel
Chemo or Immune Therapy: Paul Bunn
4:00PM
Expert Panel Discussion and Q&A Moderator: Paul Bunn
4:20PM
Clinical Pathways & Value-Based Care: Optimizing Therapies to improve NSCLC Outcomes
Jim Koeller
RAPID-FIRE Questions
  1. I understand how value is defined for anti-cancer therapy. Yes? No?
  2. I understand what is meant by a clinical pathway for lung cancer care. Yes? No? ‘
  3. Most payers consider _____% compliance acceptable for clinical pathways. A) at least 50% B) approximately 60% C) approximately 70% D) approximately 80%
Content Highlights
  • Identify all of the components involving all aspects of diagnosis and therapy of NSCLC in to order to develop an optimal therapy
  • Identify the clinical and financial benefits of a NSCLC pathway as it relates to patient care, resource utilization -- including testing, drug selection, pathway compliance and outcomes.
  • Which clinical pathways are viable options to everyone? How does an oncologist best select the most appropriate options? Pros and cons? Why? What is the future?
  • How are specific NSCLC pathways developed, implemented, used and monitored? What is the future?
4:40PM
Q&A
4:50PM
POST-TEST for CME/CE - Steve Madison
5:00PM
Graduation and Wall Plaques Issued

Master Class Objective & Executive Summary top

The overall objective of this live, 2-day lung cancer master class, and the archived Internet webinars as enduring materials for one year available approximately 3 months following the live program in Dallas, is to provide much needed lung cancer training to the executives within pharmaceutical companies and diagnostic/laboratory companies, especially those who are new or relatively new to lung cancer. In addition, this lung cancer training initiative is also designed to help non-industry Health Care Professionals (HCPs) who provide patient care, to better understand the most recent clinical developments regarding lung cancer therapeutics, supportive care products and diagnostics.

The FOCUS of this two-day Master Class will be on the most important and most common areas of what lung cancer drugs, supportive care and diagnostic tests are used. Recognizing the time constraints of a two-day agenda certain areas will receive more time than others, reflecting, as best as possible, the relative proportion of how lung cancer is treated today. For example, a large percentage of the two-days will be devoted to metastatic NSCLC. Special topics such as “Should Stereotactic Ablation Body Radiation (SABR) be considered as an equivalent, alternative standard of care to surgery for stage I NSCLC patients," will not be included on the agenda. Rather, a slight discussion on the treatment and management of early-stage (I-IIIA) NSCLC cancer will be addressed.

The Master Class agenda has been structured so that the expert lung cancer KOL faculty helps pharmaceutical and diagnostic companies to provide better service to their customers: the oncologists, pathologists, fellows, nurses pharmacists and other HCPs involved in delivering care to lung cancer patients.

What makes this Master Class so unique is that it is a CME/CE-accredited or certified course that utilizes academic and cancer leaders in ancillary areas as the course faculty. The Oncology Learning Center (OLC) has accredited this course for 16 hours of CME/CE credit because many, if not the majority of the executives within pharmaceutical and diagnostic/laboratory companies, are physicians, nurses, pharmacists and other HCPs. THE OLC has also intentionally made this Master Class a CME/CE event so that no commercial interests could be a part of the faculty and to help avoid any type of commercial influence. This Master Class is therefore an objective, unbiased review of the current and emerging therapies, diagnostics and supportive care for lung cancer.

Outside of this Master Class, pharmaceutical industry and diagnostic industry professionals of various health care disciplines have very limited opportunities to engage with the KOLs who for the most part are the experts who are typically any or all of the following: Principal Investigators of key lung cancer clinical trials; authors of publications and abstracts from key lung cancer trials; authors of many textbook chapters on lung cancer; committee members of various guidelines and other professional lung cancer organizations such as the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology.

Therefore, we have designed this 2-day Master Class to focus on the needs that are based upon medical and scientific research that both the clinical and marketing pharmaceutical industry executives must thoroughly understand in order to be proficient in their various industry positions involving drugs, diagnostics and supportive care for lung cancer.

The comprehensive agenda on this Website describes in great detail the content of this Lung Cancer Master Class. In addition, the expert academic and leading ancillary expert faculty members and their biographies are provided.

The educational format or learning design of this Master Class is one that is intentionally highly interactive. From the beginning through the final panel discussion, all presentations, session and panels are structured so that the audience can ask questions of the expert faculty. And vice-versa, the faculty will be asking questions of the audience throughout the entire program.

To receive CME/CE credit, the learners attending the February 2-3, 2017 Lung Cancer Master Class have two weeks following the program to complete the required program survey (on line), and to successfully answer the knowledge test questions found on Oncology Learning Center (OLC) Website for this Master Class. All of the PowerPoint® slides, recorded audio and PowerPoint slide presentations will be available for download and "24/7" immediately following the Master Class.

NOTE: Bring your own "Smart Devices" to interact with the faculty
Please bring your iPhones, iPads, Tablets, Androids, Laptop Computers, etc., to the February 2-3, 2017, Lung Cancer Master Class. (If you forget, we will have a few extras for you to use in Dallas.) Smart Devices connected to our private Master Cass Network will enable you and the other Master Class participants to use your personal "smart devices" to ask any questions of the faculty throughout the 20day program from your seats in the audience, and also, to enable you and others in the audience to answer the numerous lung cancer questions of each faculty member during their presentations.

Educational Need

In 2016, lung cancer was the leading cause of cancer deaths in the US, remains a significant unmet medical need, and, is expected to be a major clinical and scientific challenge for the foreseeable future, but with modest incremental advances. According to the American Cancer Society Facts and Figures there were an estimated 225,000 new cases, and 160,000 deaths from lung cancer this in 2016. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer.Despite the overall poor outcome, lung cancer patient outcomes are improving. Patients are living longer and with a better quality of life because physicians and other healthcare professionals have access to the information to gain the knowledge and competence to treat, care for and manage their patients. Physicians have a better understanding of lung cancer cell biology, an increasing ability to personalize existing and emerging systemic lung cancer drug therapy because of molecular and genomic diagnostic tests, the availability to use next-generation systemic lung cancer therapy and expanded uses of many existing systemic lung cancer drug therapies.

Target Audience top

The target audience for this CME/CE Lung Cancer Master Class is primarily the pharmaceutical/diagnostic industry executives who are involved in the area of lung cancer: either in drug cancer development or commercialization. A large and an increasing number of executives holding various medical, research, marketing, sales and other vital positions within drug and diagnostic companies involved in lung cancer, have clinical, scientific or advanced healthcare degrees and licenses, such as NPs, oncologists, pharmacists, nurses, Nurse Practitioners, Physician assistants, PhDs, dieticians and other physicians and Health Care Professionals (HCPs) and have chosen to utilize their HCP degrees for careers within pharmaceutical, biotech and diagnostic/laboratory companies, and ancillary companies such as medical advertising and communications companies. In addition, all HCPs, including oncologists, physicians nurse, pharmacists and other HCPs, in either private practice or academia, who are interested in this Master Class CME/CE activity are invited to attend. And finally, anyone else who may not be a HCP, but rather are important and integral members of the chain of professionals involved in the delivery of care to cancer patients are also invited to “audit this Master Class for no CME/CE credit.” This is especially true for many marketing and sales executive but it also includes consultants, and other corollary personnel involved in lung cancer. The inclusion of everyone from various backgrounds, especially in a limited group of 70 participants, will only help to facilitate an important interactive dialogue during this two-day Master Class.

Learning Objectives

Physicians

  1. Understand the epidemiology and etiology of lung cancer.
  2. Analyze the “driver” mutations” in NSCLC and their importance to therapy.
  3. Compare and contrast the differences between traditional molecular testing (e.g., IHC, FISH) and genomic testing (e.g., NGCS and gene signatures) and their different applications.
  4. Evaluate the differences between the various approved and emerging immune checkpoint inhibition strategies for NSCLC patients in the relapsed and treatment-naïve settings.
  5. Compare and contrast all three of the existing classes of lung cancer therapy including immune therapy, novel chemotherapy and targeted therapy for NSCLC patients across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  6. Analyze the various options for dual drug therapy including experimental therapeutic strategies using dual immune oncology therapy, immune therapy plus a targeted therapy, a chemotherapy plus a targeted therapy or a chemotherapy plus an immune therapy.
  7. Understand how to devise personalized, systemic, NSCLC treatment strategies based upon the results of Next-Generation Sequencing (NGS) testing.
  8. Compare and contrast the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies versus tissue biopsies to help guide therapy selections.
  9. Understand the pros and cons of lung cancer clinical pathways on therapeutic efficacy.
  10. Describe how the early use of supportive care for NSCLC improves patient outcomes, including overall survival.

Pharmacist

  1. Describe the epidemiology and etiology of lung cancer.
  2. Identify the “driver” mutations” in NSCLC and their importance to therapy.
  3. Define the differences between traditional molecular testing (e.g., IHC, FISH) and genomic testing (e.g., NGCS and gene signatures) and their different applications.
  4. List the differences between the various approved and emerging immune checkpoint inhibition strategies for NSCLC patients in the relapsed and treatment-naïve settings.
  5. Describe all three of the existing classes of lung cancer therapy including immune therapy, novel chemotherapy and targeted therapy for NSCLC patients across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  6. Recall the various options for dual drug therapy including experimental therapeutic strategies using dual immune oncology therapy, immune therapy plus a targeted therapy, a chemotherapy plus a targeted therapy or a chemotherapy plus an immune therapy.
  7. Describe how to devise personalized, systemic, NSCLC treatment strategies based upon the results of Next-Generation Sequencing (NGS) testing.
  8. Identify the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies versus tissue biopsies to help guide therapy selections.
  9. List the pros and cons of lung cancer clinical pathways on therapeutic efficacy.
  10. Describe how the early use of supportive care for NSCLC improves patient outcomes, including overall survival.

Nurses and Advanced Nurse Practitioners

  1. Describe the epidemiology and etiology of lung cancer.
  2. Identify the “driver” mutations” in NSCLC and their importance to therapy.
  3. Define the differences between traditional molecular testing (e.g., IHC, FISH) and genomic testing (e.g., NGCS and gene signatures) and their different applications.
  4. List the differences between the various approved and emerging immune checkpoint inhibition strategies for NSCLC patients in the relapsed and treatment-naïve settings.
  5. Describe all three of the existing classes of lung cancer therapy including immune therapy, novel chemotherapy and targeted therapy for NSCLC patients across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  6. Recall the various options for dual drug therapy including experimental therapeutic strategies using dual immune oncology therapy, immune therapy plus a targeted therapy, a chemotherapy plus a targeted therapy or a chemotherapy plus an immune therapy.
  7. Describe how to devise personalized, systemic, NSCLC treatment strategies based upon the results of Next-Generation Sequencing (NGS) testing.
  8. Identify the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies versus tissue biopsies to help guide therapy selections.
  9. List the pros and cons of lung cancer clinical pathways on therapeutic efficacy.
  10. Describe how the early use of supportive care for NSCLC improves patient outcomes, including overall survival.

CME & CE Credit top

This symposium provides 16 hours of CME credit to physicians, 16 hours of CNE credit to nurses, 16 hours of CPE credit to pharmacists, and a Certificate of Attendance for fellows and other HCPs for receiving 16 hours of credit from their professional organizations and accrediting societies.

Accreditation Statements top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-17-001-L01-P
Credits: 16 hours (1.6 ceus)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 16 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 16 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Hotel (Location) top

The February 2-3, 2017 Lung Cancer Master Class will be conducted at the Hyatt Regency Hotel located in Terminal C which is very conveniently located inside the Dallas/Ft. Forth (DFW) International Airport.

We have secured 70 sleeping rooms at a discounted room rate of $209 per night (single and double occupancy) at the Hyatt Regency DFW. Triple occupancy is $234. Quadruple occupancy is $259. All of these discounted rates are exclusive of applicable taxes which are estimated at 13%.

The contact information of the Hyatt Regency is:
2334 North International Parkway
DFW Airport, TX, 75261
Telephone: 972-453-1234

The Hyatt Regency recommends using Passkey to make your web-based sleeping room reservations. Passkey is made available by Hotel on a complimentary basis, and provides an electronic reservations interface that is customized for the Event.

“Click here on the Passkey to reserve your sleeping room.”

Reservations may be made, modified or cancelled by attendees using Passkey. All information is confidential between the Hyatt Regency and the guest. Reservations for rooms accessible to guests with disabilities may be made in the same manner. Reservations must be made on or before the Cut-Off Date which is January 18, 2017.

Individuals will also be able to make, modify or cancel reservations by calling 888-421-1442 toll free and referring to Group, Event name or Event code. Reservations must be made on or before the Cut-Off Date of January 18, 2017.

Airline Transportation (Very Important Information) top

For the convenience of all participants of the forthcoming February 2-3, 2017 Lung Cancer Master Class we have selected the Hyatt Regency Hotel, inside Terminal C of the Dallas/Ft. Worth International Airport, for conducting the actual 2-day Master Class and for all sleeping rooms.

Please note #1: There are two Hyatt hotels located inside the Dallas (DFW) Ft. Worth International Airport. One is the Hyatt Regency (inside Terminal C) where the Lung Cancer Master Class will be held and where we have reserved 70 sleeping rooms at a special discounted rate. Detailed hotel information is provided below.

Please note #2: As is the situation in many cities in the United States, there is another major airport servicing the Dallas and Ft. Worth, Texas cities and surrounding areas: That airport is Dallas Love Field which is the national (US) hub and headquarters of Southwest Airlines.

The Dallas Love Field airport is located approximately 30 miles away from Dallas Fort Worth (DFW) International airport, where the February 2-3, 2017 Lung Cancer Master Class will be conducted. Depending upon ground automobile traffic this will be between a 30-and 90-minute taxi drive between these two airports (Dallas Love Field and DFW International) plus approximately an $80 taxi fare. Also, please note that Southwest Airlines DOES NOT service Dallas Ft. Worth (DFW) International Airport.

Therefore, it is highly advisable that all executives flying to Dallas to attend the February 2-3, 2017 Lung Cancer Master Class use an airline that flies to Dallas Ft. Worth (DFW) International airport (the location of the Lung Cancer Master Class) and NOT to Dallas Love Field which is mandatory if you fly Southwest Airlines. Southwest does not fly to Dallas Fort Worth International Airport (DFW).

Privacy Policy

Our privacy policy is that any information provided by any participant will not be sold or distributed outside of the Oncology Learning Center, Inc. Information you provide will be used only to contact you for our other Oncology Learning Center Master Classes or other training courses. You may opt out of our mailing list at any time by contacting us at registration@OncologyLearningCenter.com or call 214-269-2014 and leave a detailed message.

  • Pharmaceutical executives who are new or relatively new to lung cancer, working on either therapeutics, supportive care products and diagnostics.
    • Medical Affairs, Clinical development, R & D
    • MSLs (Medical Scientific Liaisons)
    • Marketing, Marketing Research
    • Sales Management/Sales
    • Commercial development, Business Development
    • KOL/ Thought Leader management and liaisons
    • Training Directors, Managers and Associates
    • Strategic planning and development
  • Executives with experience in lung cancer
  • Advertising Agency Executives and Writers, Market Research Companies
  • Medical Communication Executives and Writers
  • Consultants
  • Publication Planners
  • Clinical Research Organizations (CROs), Investment Bankers
  • A limited number of private-practice oncologists, nurses, pharmacists, and other HCPs
  • It is hoped that the participants have a basic understanding of efficacy endpoints such as Kaplan Meier Survival Curves, Response Rates, Time-based clinical endpoints such as Progression-Free Survival, Overall Survival, Hazard Ratios and other measurements of efficacy. Similarly, it is assumed that the participants will have a basic understanding of cancer toxicities e.g., Toxicity Grades 1-4 from the lung cancer drugs and a basic understanding of Performance Status and other common elements related to the treatment and management of lung cancer patients. These topics were reviewed in depth at the October 19-21, 2016 Strategic Cancer Business Master Class in Dallas.
  • PLEASE NOTE: If a participant needs assistance on these fundamental topics he/she is highly encouraged to do some self-study using the Internet and gain a basic understanding of these fundamental concepts prior to taking this Lung Cancer Master Class. Also, some relevant basic materials should be available by January 2017. Contact us if you are interested in purchasing any basic material to prepare for this lung cancer class.
  • This Lung Cancer Master Class is the ONLY practical and cost-effective way for anyone to become current regarding the information that a pharmaceutical industry executive needs to know in a two-day period.
  • This Lung Cancer Master Class is the ONLY practical and cost-effective way for anyone to get to know, personally, most of the country’s top-tier KOLs in lung cancer.
  • Attending this Lung Cancer Master Class provides a major benefit: establishing personal relationships with the lung cancer KOLs while learning lung cancer in an immersion course.
  • This Lung Cancer Master Class is only offered ONCE every four years.
  • No other such lung cancer immersion training course exists.
  • Today, there is so much new information on so many current, new and emerging lung cancer therapeutics, supportive care products and diagnostics, as well as new indications for existing lung cancer drugs.
  • Within the R&D pipelines of numerous pharmaceutical companies, there is an ever increasing number of lung cancer therapeutics, supportive care products and diagnostics, many of which will become FDA approved.
  • For example, as of October 2016, there are three FDA approved checkpoint inhibitors (immune therapies) for lung cancer. And numerous others are in late-stage development and several are expected to be approved in 2017. Similarly, there are nearly ten targeted therapies that are FDA approved for known targets in NSCLC with many more in late-stage development.
  • Can you afford not to attend this Master Class on lung cancer and not to be the most competitive within your industry regarding lung cancer?
  • Because this Master Class is taught by the top-tier expert KOLs in lung cancer, it affords a rare opportunity to personally meet and get to know the KOLs.
  • During the two days of the program, there is a one-hour welcome reception on day one, plus several meal functions where individual KOL faculty members are assigned separate tables to enable pharmaceutical industry participants to sit with the KOLs of their choice: one formal dinner, two buffet breakfasts, and two buffet lunches. There are also four beverage breaks. With a limit of only 70 participants there is ample time for personal meetings with the KOLs.
  • In most oncology pharmaceutical companies, only the sales representatives receive formal lung cancer training of any kind. In addition, your customers, the practicing oncologists, hematologists and other cancer HCPs are required to take 30 hours of oncology/hematology CME or CE training annually. Therefore, how do cancer executives like yourself receive this essential training? How do you keep current? How do retain your competitive advantage, especially with the KOLs?
  • Private practice medical oncologists/hematologists and related cancer HCPs will benefit from this three-day update by the academic experts and by networking with the pharmaceutical/diagnostic industry executives.
© 2017 Oncology Learning Center, Inc.